Evidence map›Paper›PMID 35844892›Full record

ArticleFrontiers in public health2022

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.

Hong Zhu, Jingmin Zhu, Yingyu Zhou, Linghan Shan, Cui Li, Yu Cui, Zheng Kang, Mingli Jiao, Huan Liu, Lijun Gao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hong ZhuDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Jingmin ZhuDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Yingyu ZhouScience and Technology Development Center, Chinese Pharmaceutical Association, Beijing, China.
Linghan ShanDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Cui LiDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Yu CuiDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Zheng KangDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Mingli JiaoDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Huan LiuDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Lijun GaoDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Qunhong WuDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.
Yanhua HaoDepartment of Health Policy, Health Management College, Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Since 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on the accessibility of these 18 anticancer drugs in China. Methods: National hospital procurement data were collected from 2015 to 2019. As measurements of drug accessibility, monthly average of drug availability or defined daily dose cost (DDDc) was calculated. Interrupted time series (ITS) analysis was employed to evaluate the impact of NRDLN on drug accessibility. Multilevel growth curve models were estimated for different drug categories, regions or levels of hospitals. Results: The overall availability of 18 anticancer drugs increased from about 10.5% in 2015 to slightly over 30% in 2019. The average DDDc dropped from 527.93 CNY in 2015 to 401.87 CNY in 2019, with a reduction of 23.88%. The implementation of NRDLN was associated with higher availability and lower costs for all 18 anticancer drugs. We found an increasing level in monthly drug availability (β Conclusion: The implementation of NRDLN improves the availability and reduces the cost of some anticancer drugs in China. It contributes to promoting accessibility of anticancer drugs, as well as relieving regional or hospital-level disparities. However, there are still challenges to benefit more patients sufficiently and equally. It requires more policy efforts and collaborative policy combination.

Indexed as

Antineoplastic AgentsDrug CostsChinaHealth PolicyHumansInterrupted Time Series AnalysisNegotiatingAntineoplastic Agentsaccessibilityanticancer drugsavailabilityChinacostNational Reimbursement Drug List Negotiation

Identifiers

PMID35844892
PMCPMC9283976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.